In vitro (inhibition of HGF-induced activation of the MET in human mesothelioma, B16-F10 melanoma, and lung cancer cell lines); in vivo (inhibition of HGF in the PC-9 mouse xenograft model). This evidence concerns the gene HGF and lung carcinoma.